Man Group’s Carisma Therapeutics CARM Stock Holding History

Man Group’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-637	Closed	-$17K	–	1862
2020 Q4	$17K	Buy	+637	New	+$16.2K	﹤0.01%	1803

Other funds holding CARM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Man Group's CARM Position: Q1 2021 in Review

Man Group sold out of Carisma Therapeutics (CARM) in Q1 2021, closing a stake of 637 shares — an estimated $17K sold.

Man Group first reported a position in CARM in Q4 2020 and held it in 1 quarter. The position peaked at $17K in Q4 2020. 76 funds tracked by Wall St. Rank hold CARM as of Q1 2021.

Man Group reported no remaining Carisma Therapeutics position as of Q1 2021 after selling out during the quarter.
Man Group sold 637 Carisma Therapeutics shares in Q1 2021, an estimated $17K.
Man Group first reported a position in Carisma Therapeutics in Q4 2020 and held it in 1 quarter.
Man Group's Carisma Therapeutics position peaked at $17K in Q4 2020.
76 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2021.

Based on Man Group's 13F filing for Q1 2021, filed 17 May 2021.